Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.5K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.5K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

309
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
309
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

447
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
447
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

106
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
106
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

467
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
467
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

73
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI counseling agent for motivational interviewing: Conversational processes associated with change talk in emergency department patients.

Journal of substance use and addiction treatment·2026
Same author

The Role of Ventricular Arrhythmias Inducibility in Arrhythmic Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy: A Meta-Analysis of Observational Studies.

Journal of arrhythmia·2025
Same author

Feasibility and Acceptability of a Large Language Model-Based Motivational Interviewing Agent in the Emergency Department.

Annals of emergency medicine·2025
Same author

QPRapp: A Web-Based Platform for PK/PD Simulations and Early Feasibility Analysis.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Application of machine learning in combination with mechanistic modeling to predict plasma exposure of small molecules.

Frontiers in systems biology·2025
Same author

Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies.

mAbs·2025

Related Experiment Video

Updated: Mar 21, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

2.0K

Machine-learning-enabled modeling of pharmacokinetics and pharmacodynamics.

Yorgos M Psarellis1, Nikhil Pillai1, Saroj Dhakal1

  • 1Quantitative Pharmacology & Pharmacometrics, Translational Medicine Unit, Sanofi US, Cambridge, MA, USA.

Drug Discovery Today
|March 19, 2026
PubMed
Summary

Machine learning (ML) and artificial intelligence (AI) are increasingly used in computational modeling for pharmacokinetics (PK) and pharmacodynamics (PD) assessments. This review categorizes AI/ML methods for PK/PD analysis to guide their application in time-course modeling.

Keywords:
Machine learningcomputational pharmacologymodelingpharmacodynamicspharmacokineticsscientific computingtranslational medicine

More Related Videos

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Related Experiment Videos

Last Updated: Mar 21, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

2.0K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Area of Science:

  • Pharmacometrics
  • Computational Biology
  • Machine Learning

Background:

  • Computational modeling is crucial for pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
  • The pharmacometrics field is integrating machine learning (ML) and artificial intelligence (AI) for enhanced pharmacology.
  • AI/ML offers potential benefits like faster assessments, reduced costs, and improved patient safety.

Purpose of the Study:

  • To review and stratify existing AI/ML approaches for PK/PD analysis.
  • To position AI/ML methods within the broader scientific computing landscape for PK/PD.
  • To examine how AI/ML can contribute to PK/PD time-course modeling.

Main Methods:

  • Literature review of AI/ML applications in PK/PD modeling.
  • Categorization of AI/ML techniques based on data availability and research questions.
  • Analysis of AI/ML's role in PK/PD time-course modeling.

Main Results:

  • AI/ML offers diverse applications in PK/PD modeling, adaptable to different data scenarios.
  • Stratification of AI/ML approaches provides a framework for their use in PK/PD analysis.
  • The integration of AI/ML enhances the capabilities of computational modeling in pharmacology.

Conclusions:

  • AI/ML presents significant opportunities to advance PK/PD time-course modeling.
  • Strategic application of AI/ML can optimize drug development and patient care.
  • Further exploration and integration of AI/ML are recommended for the pharmacometrics community.